Leishmania species metabolic pathways

“Leishmania species metabolic pathways” refers not to a single molecule or receptor, but to the integrated network of biochemical routes (including glycolysis, gluconeogenesis, sterol biosynthesis, folate and purine salvage, lipid, and amino acid metabolism) that enable Leishmania parasites to grow, differentiate, adapt to hostile environments (e.g., human macrophage phagolysosome, sandfly gut), and evade host immune responses. Unlike mammals, Leishmania lacks de novo purine synthesis and therefore relies on highly evolved salvage pathways with unique enzymatic activities; similarly, their folate metabolism and sterol biosynthetic enzymes possess unique features that can serve as potential drug targets. Pharmacological inhibition of key metabolic enzymes (e.g., sterol 14α-demethylase, dihydrofolate reductase-thymidylate synthase, trypanothione reductase) has been exploited in anti-leishmanial drug development. However, the term encompasses many distinct targets; therefore, it is not a canonical therapeutic target itself, but a category containing multiple molecular targets with varying druggability, essentiality, and selectivity for the parasite. Use of "Leishmania species metabolic pathways" as a target is too broad and not appropriate for highly structured target annotation—individual enzymes or transporter proteins are the correct entities for deeper analysis.

Other names

Leishmania metabolic pathwaysLeishmania biochemical pathwaysLeishmania parasite metabolism

Inhibition of sterol biosynthesis (e.g., azoles targeting sterol 14α-demethylase); Disruption of folate metabolism and nucleotide synthesis (antifolates); Interference with lipid/energy metabolism (miltefosine, amphotericin B); Inhibition of protein synthesis (paromomycin); Disruption of thiol redox homeostasis (antimonials, trypanothione pathway inhibitors)